Mammoth Biosciences
Ngan Nguyen has extensive experience in research and development roles within the biosciences field, currently serving as a Senior Research Associate at Mammoth Biosciences since January 2022, focusing on gene editing and viral delivery for extrahepatic diseases. Prior to this, Ngan held multiple positions at Guardant Health from October 2019 to January 2022, contributing as a Research Associate, Biorepository Technician, and Accessioner. Ngan's career began at UCLA Department of Molecular, Cellular, and Developmental Biology as a Lab Assistant from April 2018 to February 2019. Ngan holds a Bachelor of Science degree in Microbiology, Immunology, and Molecular Genetics from UCLA, earned between 2017 and 2019.
This person is not in any offices
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.